Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
Phase 3 Terminated
102 enrolled
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Phase 1/2 Terminated
110 enrolled
ITIL-306 in Advanced Solid Tumors
Phase 1 Terminated
1 enrolled
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Phase 1 Terminated
91 enrolled
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Phase 1 Terminated
34 enrolled
TAS3351
Phase 1 Terminated
18 enrolled 22 charts
A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients
Phase 1/2 Terminated
19 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled 43 charts
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
Phase 1 Terminated
24 enrolled
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Phase 1 Terminated
4 enrolled
ALAFOSS-01
Phase 1 Terminated
17 enrolled
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Phase 1/2 Terminated
28 enrolled
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Phase 2 Terminated
50 enrolled 18 charts
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Phase 1/2 Terminated
59 enrolled
AcceleRET-Lung
Phase 3 Terminated
223 enrolled 18 charts
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Phase 1 Terminated
29 enrolled
CANOPY-1
Phase 3 Terminated
673 enrolled 38 charts
PRO1107 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
33 enrolled
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
21 enrolled
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Phase 1 Terminated
64 enrolled
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
Phase 1 Terminated
30 enrolled
Tamarack
Phase 2 Terminated
192 enrolled 20 charts
Microwave Ablation in Chinese Patients With Lung Tumors
Phase NA Terminated
13 enrolled 11 charts
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Phase 1 Terminated
42 enrolled
A Study of PHN-010 in Patients With Advanced Solid Tumors
Phase 1 Terminated
26 enrolled
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
61 enrolled 29 charts
Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
Phase 1 Terminated
9 enrolled
This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091
Phase 1 Terminated
8 enrolled 10 charts
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Phase 1/2 Terminated
34 enrolled 44 charts
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Phase 1 Terminated
250 enrolled
C-TIL051 in Non-Small Cell Lung Cancer
Phase 1 Terminated
1 enrolled
HBI-8000
Phase 2 Terminated
5 enrolled 8 charts
KZR-261 in Subjects With Advanced Solid Malignancies
Phase 1 Terminated
61 enrolled 25 charts
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
Phase 1/2 Terminated
36 enrolled
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
Phase 1 Terminated
227 enrolled
KEYNOTE-867
Phase 3 Terminated
448 enrolled 24 charts
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Phase 2 Terminated
77 enrolled 18 charts
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Phase 1/2 Terminated
95 enrolled
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
Phase 3 Terminated
162 enrolled
POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
Phase NA Terminated
12 enrolled 14 charts
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Phase 1/2 Terminated
31 enrolled
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Phase 2 Terminated
166 enrolled 43 charts
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
53 enrolled 23 charts
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Phase 1/2 Terminated
8 enrolled 12 charts
Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer
Phase 1 Terminated
41 enrolled
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
116 enrolled 36 charts
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
Phase 1 Terminated
30 enrolled